Syra Health CORP

Syra Health Corp. announced the results of its Annual Meeting of Stockholders held on July 23, 2026, detailing director elections, auditor ratification, and equity incentive plan amendments.

Syra Health announced its first profitable quarter in Q1 2026, with net income of $241,000, driven by revenue growth and margin expansion.

Syra Health Corp. announced significant improvements in its FY2025 financial results, including a 157% growth in population health revenue and a 76% reduction in net loss, with a target to achieve profitability by year-end 2026.

Syra Health Corp. announced the appointment of Gregory R. Alexander, a seasoned healthcare executive and former U.S. Marine, as its new Chief Executive Officer, effective January 5, 2026.

Syra Health Corp. has amended its Certificate of Incorporation to modify the transferability and conversion rules for its Class B Common Stock, effective November 18, 2025.

Syra Health Corp. stockholders approved all five director nominees, ratified its auditor, and passed two amendments related to Class B common stock at its Annual Meeting.

Syra Health reports a return to profitability in Q1 2026 with net income of $240,979, driven by growth in population health services.

Syra Health Corp. reported a reduced net loss for the third quarter and nine months ended September 30, 2025, despite an overall revenue decline and ongoing liquidity concerns.

Syra Health Corp. reported a significant reduction in net loss for Q2 2025, driven by improved gross margins and cost reductions, despite a shift in revenue mix from healthcare workforce to population health services.

Syra Health Corp.'s Q1 2025 results show a slight revenue increase and a significant reduction in net loss compared to the same period last year.

Syra Health Corp. announced a net loss of $417,535 for the third quarter of 2024, an increase from the previous year's loss, despite a 42% rise in net revenues.

Syra Health Corp. reported a net loss of $1.39 million for the second quarter of 2024, compared to a net loss of $802,800 in the same period last year, as the company continues to invest in growth and expansion.

Syra Health Corp. files Amendment No. 1 to its Form 10-K for the fiscal year ended December 31, 2025, to include previously omitted Part III information.

Syra Health Corp. reported a significantly reduced net loss for 2025, despite a 9% revenue decrease, while facing a going concern warning and delisting from Nasdaq.

Syra Health Corp.'s annual report reveals revenue growth alongside ongoing concerns about its ability to continue as a going concern without additional financing.

Syra Health Corp.'s 10-K filing outlines its dual-class share structure, financial performance, and future strategies in the healthcare services sector.

Syra Health Corp. Director Vijayapal Reddy acquired 43,348 stock options with a $0.07 exercise price, vesting over three years.

Syra Health Corp. Director Ketan Paranjape acquired 43,348 stock options with a $0.07 exercise price, vesting over three years.

Syra Health Corp. Director Avutu Reddy acquired 43,348 stock options with a $0.07 exercise price, vesting over three years.

Director Andrew Dahlem of Syra Health Corp acquired 9,102 stock options on January 7, 2025, as part of the company's 2022 Omnibus Equity Incentive Plan.

A Syra Health Corp director, Vijayapal Reddy, acquired 12,136 stock options on January 7, 2025, under the company's 2022 Omnibus Equity Incentive Plan.

A Syra Health Corp director, Sherron Rogers, acquired 9,102 stock options at an exercise price of $0.7386 on January 7, 2025.

Syra Health Corp. has issued a proxy statement for its 2026 Annual Meeting of Stockholders, scheduled for July 23, 2026, detailing proposals for director elections, auditor ratification, and an equity incentive plan amendment.

SYRA Health Corp. has filed a definitive proxy statement with the SEC, outlining proposals for an upcoming shareholder meeting.

Syra Health Corp. announced its 2025 Annual Meeting of Stockholders to elect directors, ratify auditors, and vote on amendments to Class B Common Stock conversion and transfer rules.

Syra Health Corp. has filed a definitive proxy statement with the SEC.

Syra Health Corp. will hold its annual meeting of stockholders on June 18, 2024, to elect eight directors and ratify the appointment of M&K CPAS, PLLC as its independent accounting firm.

Syra Health Corp. plans to offer shares of Class A common stock, along with Series A and Series B warrants, and pre-funded warrants in a public offering.

Neil Johnson has reported a 6.2% beneficial ownership stake in Syra Health Corp, acquired with personal funds for the purpose of influence.